All data are based on the daily closing price as of November 18, 2026
o
Oneness Biotech
4743.TWO
1.33 USD
-0.08
-5.67%
Overview
Last close
1.33 usd
Market cap
637.76M usd
52 week high
2.59 usd
52 week low
1.27 usd
Target price
9.35 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
150.0529
Price/Book Value
2.345
Enterprise Value
552.94M usd
EV/Revenue
130.0892
EV/EBITDA
141.176
Key financials
Revenue TTM
4.25M usd
Gross Profit TTM
1.39M usd
EBITDA TTM
-16.72M usd
Earnings per Share
-0.01 usd
Dividend
N/A usd
Total assets
342.45M usd
Net debt
N/A usd
About
Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceuticals, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation and Organic Food segments. The company offers Fespixon which is a treatment of diabetic foot ulcer; and Bonvadis, a wound care medical device. It also develops FB825, which is in Phase II clinical trial for treating atopic dermatitis and allergic asthma; FB704A which is in Phase II clinical trial for the treatment of rheumatoid arthritis and inhibiting tumor angiogenesis; SNS812, which is in Phase II clinical trial for the treatment of COVID; and SNS851 which is in clinical development for potential applications in metabolic diseases such as obesity, diabetes, hypercholesterolemia, and fatty liver disease. In addition, the company is involved in the management of agriculture cultivation and organic food trading business; and sale of organic food, dietary supplements, and beverages. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.